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OBJECTIVE — Althoughabdominalobesityandrelatedmetabolicabnormalitiesarehypoth-
esized to promote colorectal carcinogenesis, direct conﬁrmation of this effect is required. Here,
we examined the relation of early-stage colorectal neoplasia to visceral fat area and markers of
insulin resistance.
RESEARCH DESIGN AND METHODS — Subjects were participants in a comprehen-
sive health screening conducted at the Hitachi Health Care Center, Ibaraki, Japan. During a
3-year period (2004–2007), a total of 108 patients with early-stage colorectal neoplasia, includ-
ing 22 with early cancer, were identiﬁed among individuals who received both colorectal cancer
screening and abdominal computed tomography scanning. Three control subjects matched to
each case subject were randomly selected from those whose screening results were negative.
Conditional logistic regression analysis was used to examine the association of measures of
obesityandmarkersofinsulinresistancewithcolorectalneoplasia,withadjustmentforsmoking
and alcohol drinking.
RESULTS — Visceral fat area, but not subcutaneous fat area, was signiﬁcantly positively
associated with colorectal cancer, with odds ratios (95% CI) for the lowest to highest tertile of
visceral fat area of 1 (reference), 2.17 (0.45–10.46), and 5.92 (1.22–28.65), respectively
(Ptrend  0.02). Markers of insulin resistance, particularly fasting glucose, were also positively
associated with colorectal cancer risk. In contrast, no associations were observed for colorectal
adenomas.
CONCLUSIONS — These results suggest that visceral adipose tissue accumulation and in-
sulin resistance may promote the development of early-stage cancer but not adenoma in the
colorectum.
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lthough the role of obesity as a
strong predictor of various chronic
diseases, including type 2 diabetes
and cardiovascular disease, has been es-
tablished, accumulating evidence also in-
dicates the importance of obesity and its
related metabolic disorders in the devel-
opment of cancer (1). In Japan, the inci-
dence of colorectal cancer has sharply
increased over the last several decades
and is now among the highest in the
world(2).Thistimetrend,aswellasﬁnd-
ings from migrant studies (3), suggests
the involvement of environmental factors
in colorectal carcinogenesis. Epidemio-
logicalstudies(4,5)haveshownthatcolo-
rectal cancer risk is more strongly
associated with waist circumference than
with BMI, indicating the etiological im-
portance of abdominal or visceral fat dis-
position, rather than overall adiposity.
However, given that waist circumference
is only a surrogate of visceral fat mass,
more direct evidence is required before
the link between visceral adiposity and
cancer risk can be considered conclusive.
Several studies have assessed the as-
sociation between visceral fat area, as
measured using computed tomography
(CT) scanning, and colorectal neoplasia
(6–10), but results have been mixed. For
example, a Japanese study (7) demon-
strated an increased prevalence of colo-
rectal adenomas among individuals with
higher visceral fat area, whereas a larger,
more recent study (8) did not. Given that
adenomatous polyps are common but
only a minority progress to cancer (11),
theassociationwithcancershouldalsobe
explored, but evidence to date is sparse.
In a Turkish study (10), patients with
colorectal cancer tended to have a smaller
rather than larger visceral fat area than
that in control subjects. This unexpected
ﬁnding may have been due to weight loss
in the course of cancer development,
however, a possibility that highlights the
importanceofassessingvisceralfatbefore
the diagnosis of cancer or development of
symptoms.
An insulin hypothesis has been pro-
posed to explain the observed association
between obesity or abdominal obesity
and colorectal neoplasia (12,13). Accu-
mulation of visceral fat is a strong deter-
minant of insulin resistance and
hyperinsulinemia (14) and, as experi-
mental data show (15), insulin promotes
colorectal carcinogenesis. Compatible
withtheinsulinhypothesis,epidemiolog-
ical data appear consistent in showing a
positive association between colorectal
neoplasia and markers of hyperinsulin-
emia or insulin resistance (rev. in 16).
These ﬁndings notwithstanding, how-
ever, a role for insulin resistance in pro-
moting the development of adenoma,
cancer, or both in the colorectum has yet
to be conﬁrmed. To further explore these
issues, we examined the relation of vis-
ceral fat mass assessed by CT and mea-
suresofinsulinresistancetoadenomaand
cancer in the colorectum among asymp-
tomatic individuals who underwent
screening.
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METHODS— Study subjects were
participants in a comprehensive health
examination conducted at the Hitachi
Health Care Center, Ibaraki, Japan, dur-
ing which colorectal cancer screening
and, on request, abdominal CT scanning
were performed. Abdominal CT scanning
was introduced to encourage changes in
lifestyle,suchasdietandphysicalactivity,
by showing examinees a graphic image,
togetherwithestimateddata,oftheirown
abdominal fat accumulation. In practice,
it was offered mainly to individuals who
underwent chest CT scanning for the
screening of lung cancer. Nearly one-
third of all individuals who underwent
screening chose to receive abdominal CT
assessment.Comparedwithmenwhodid
not, those who underwent abdominal CT
scanning were older (53 vs. 46 years),
were more likely to be past smokers (35
vs.22%),andtendedtohaveahigherBMI
(23.9vs.23.6kg/m
2).Incontrast,thetwo
groups were similar in terms of alcohol
drinking ( 1 go [23 g ethanol]/day: 32
vs. 29%). A go is a conventional unit of
alcohol intake in Japan.
During the 3-year period from April
2004 to March 2007, 47,224 examinees
underwent fecal occult blood testing,
which is speciﬁed as the standard proce-
dureforcolorectalcancerscreeninginthe
Japanese guidelines. Owing to limitations
in colonoscopy resources, individuals
with a positive blood test were ﬁrst in-
vited to receive a barium enema in the
health center, and only those with sus-
pected polyp lesions were referred to a
medical specialist for detailed examina-
tion by colonoscopy. Of 3,521 (8%) who
had a positive test result, half (1,738) un-
derwent barium enema at the center. Of
these, 491 (28%) with a ﬁnding suggest-
ing colorectal neoplasia were referred to
local clinics or hospitals for conﬁrmation.
Of the 280 patients who were notiﬁed by
the physicians consulted that they had
colorectal neoplasia, the present case se-
riesconsistedofthe86withhistologically
conﬁrmed adenoma and 22 with early-
stage colorectal cancer (carcinoma in situ
or cancer invading within the submu-
cosa) who received abdominal CT scan-
ning at the time of the health checkup.
Amongpatientswithadenomasofknown
size (n  82), the number with adenomas
of 10 mm in diameter was 15 (18%).
Regarding the location of cancer, 5 cases
wereintheascendingcolon,2wereinthe
transverse colon, 13 were in the sigmoid
colon, 1 was in the rectum, and 1 was not
speciﬁed. For each case subject, three
controlsubjectsmatchedbyyearofexam-
ination, sex, and age (same age) were ran-
domly selected from among examinees
who had undergone abdominal CT mea-
surement and had a negative fecal occult
blood test. No case or control subject had
a prior history of cancer, cardiac infarc-
tion, or stroke. Informed consent was ob-
tained from each examinee regarding the
use of his or her data for research pur-
poses. The protocol of the present study
was approved by the ethics committee of
the Hitachi Health Care Center.
Abdominal CT measurement
Measurementofabdominalfatareawitha
CT scanner has been detailed elsewhere
(17). In brief, single slice imaging was
done at the level of the umbilicus in the
supine position using a Redix Turbo CT
scanner (Hitachi Medico, Tokyo, Japan).
Imaging conditions, which have changed
since 2004, were 120 kV, 50 mA, and a
5-mm slice thickness. Visceral fat area,
subcutaneous fat area, and waist circum-
ference were calculated using the PC soft-
ware application fatPointer (Hitachi
Medico).
Subject characteristics and blood
measurements
Height and weight were measured using
an automated scale (Tanita BF-220) with
thepatientwearingalightgown.BMIwas
calculated as the weight in kilograms di-
vided by the square of height in meters.
Fasting plasma glucose was measured by
the glucose electrode technique using an
ADAMSGlucoseGA-1170(Arkray).Fast-
ing serum immunoreactive insulin (mi-
crounitspermilliliter)wasdeterminedby
an immunoenzymatic method using the
AxSYM insulin assay (Abbott). Ho-
meostasis model assessment of insulin re-
sistance (HOMA-IR), an index of insulin
resistance, was calculated as fasting glu-
cose multiplied by fasting insulin divided
by 405.
Covariates
Health-related lifestyles were ascertained
by questionnaire. Participants entered
their responses to the questionnaire di-
rectly into a computer using a custom-
designed data entry system. Regarding
smoking, the questionnaire inquired
about smoking status and for ever-
smokers it inquired about the duration
and intensity of smoking. For alcohol
consumption, the frequency of drinking
and the amount of alcohol consumed per
sessionwasassessedintermsofgo.Onego
contains 23 g ethanol.
Statistical analysis
Subject characteristics were compared
betweencasesubjectswithadenomasand
their matched control subjects and be-
tween case subjects with cancer and their
matched control subjects. In control sub-
jects, Pearson correlation coefﬁcients
were calculated to examine the linear as-
sociations between visceral fat area and
other exposure variables. Conditional lo-
gistic regression was used to assess the
associationofvariousobesityindexes(ab-
dominal total fat mass, visceral fat area,
subcutaneous fat area, waist circumfer-
ence, and BMI) and measures of insulin
resistance (insulin, glucose, and HOMA-
IR) with colorectal neoplasia. Odds ratios
(ORs) and 95% CIs for the prevalence of
colorectal adenoma or cancer were calcu-
lated for the second and third (highest)
tertilesofexposure,withthelowesttertile
used as reference. Cutoff values for the
exposure tertile were determined based
on the distribution among control sub-
jects for colorectal adenomas and cancer,
respectively. Analyses were performed
withandwithoutadjustmentforsmoking
(lifetime nonsmoker, ever-smoker with
1–600 cigarette-years, or ever-smoker
with 600 cigarette-years), and alcohol
consumption (nondrinker, drinker con-
suming 1 go/day, or drinker consuming
1 go/day). In analyses for the relation of
insulin resistance to visceral fat area and
blood markers, additional adjustment
was also done for BMI. All analyses were
performedusingSAS(version10;SASIn-
stitute, Cary, NC). Two-sided P  0.05
was considered statistically signiﬁcant.
RESULTS— Table 1 shows patient
characteristics for colorectal adenoma
and cancer and their respective control
subjects. Patients with colorectal adeno-
mas were more likely to smoke and con-
sume alcohol heavily than their matched
controlsubjects.Incontrast,theyhadlev-
els of obesity and markers of insulin or
insulin resistance similar to those of con-
trol subjects. Patients with colorectal can-
cer were more likely to be smokers and
alcohol drinkers than their matched con-
trol subjects and on average had a greater
BMI, waist circumference, and visceral
and subcutaneous fat area than control
subjects. Markers of insulin resistance
were higher among patients with colorec-
tal cancer than among their matched con-
trol subjects. In control subjects, visceral
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measures of obesity (Pearson correlation
coefﬁcients: waist circumference 0.82,
BMI 0.68, and subcutaneous fat mass
0.58), moderately with insulin (0.44),
and weakly with fasting glucose (0.18).
As shown in Table 2, the odds of hav-
ing colorectal cancer were increased in
subjects with a higher visceral fat mass,
with multivariable-adjusted ORs (95%
CI) for the lowest through highest tertiles
of 1 (reference), 2.17 (0.45–10.46), and
5.92 (1.22–28.65), respectively (Ptrend 
0.02). Additional adjustment for BMI did
not attenuate the association. In contrast,
subcutaneous fat mass was materially un-
related to colorectal cancer prevalence,
with a multivariable-adjusted OR for the
highest versus lowest tertile of 1.08
(0.29–4.00). Higher levels of BMI or
waist circumference were also associated
with increased prevalence of colorectal
cancer, with multivariable-adjusted ORs
(95% CI; Ptrend) for the highest versus
lowest tertile of visceral fat area of 4.38
(0.82–23.25; 0.09) and 2.03 (0.57–7.25;
0.2) for BMI and waist circumference,
respectively.Withregardtocolorectalad-
enoma, no association was seen with any
measure of obesity, including visceral fat
mass.
As shown in Table 3, the odds of
colorectal cancer tended to increase
with increasing fasting plasma glucose
concentrationand,toalesserextent,with
increasing fasting plasma insulin concen-
tration and HOMA-IR. Multivariable ORs
(95% CI; Ptrend) for the highest versus
lowest tertiles of glucose, insulin, and
HOMA-IRwere4.40(0.99–19.59;0.04),
1.84 (0.47–7.15; 0.2), and 3.10 (0.71–
13.54; 0.15), respectively. Additional
adjustmentforBMIattenuatedtheassoci-
ation with insulin and HOMA-IR but did
not greatly change that with glucose. In
contrast, no measurable association was
seenbetweencolorectaladenomaandany
of the three blood measurements.
CONCLUSIONS— Among partici-
pants in a health screening program who
underwent abdominal CT measurement,
we found increased odds of early colorec-
tal cancer in subjects with greater visceral
fat mass, but not in those with greater
subcutaneousfatmass.Markersofinsulin
resistance were also associated with a
higher prevalence of colorectal cancer. In
contrast, these associations were not ob-
served for colorectal adenoma. To our
knowledge, this study is the ﬁrst to pro-
vide direct evidence of an association be-
tween visceral adiposity and colorectal
cancer risk.
The present association between
greater visceral fat area and increased
prevalence of colorectal cancer is consis-
tent with earlier epidemiological data
showing a link between colorectal cancer
and waist circumference or waist-to-hip
ratio (4,5). In contrast, we observed no
association with subcutaneous fat mass.
Thisﬁndingindicatesthatvisceralbutnot
subcutaneous adipose tissue disposition
is involved in the promotion of colorectal
carcinogenesis. Among studies that have
measured visceral fat area using CT scan-
ning in association with colorectal neo-
plasia (6–10), only one study (10)
examined the association with colorectal
cancer. Contrary to expectations, this
studyshowedahigherprevalenceofcolo-
rectal cancer in subjects with low rather
than high visceral fat area. The authors
speculated that this ﬁnding might have
been due to weight loss induced by cancer
progression.Inourstudy,cancerinsubjects
included in the analysis was all screening-
detected and early stage, and thus the re-
sults were unlikely to have been inﬂuenced
by cancer-induced weight loss.
In contrast to the positive ﬁnding for
colorectal cancer, we observed no associ-
ation between any measure of obesity, in-
cluding visceral fat area, and the
prevalence of colorectal adenoma. Find-
ings among studies that have measured
abdominal fat area using CT are mixed: a
signiﬁcant positive association with vis-
ceraladiposityinaJapanesestudy(7)was
subsequently both supported (9) and
challenged(8,10).Further,inanancillary
study to the Polyp Prevention Trial (6),
visceral fat area measured on CT was not
associated with adenoma recurrence. The
reason for this discrepancy among ade-
noma studies is not clear. Given that
smoking is a strong determinant of both
theprevalenceofcolorectaladenoma(18)
and body weight (19), the null ﬁnding in
ourstudymightbeattributable,atleastin
part, to the high proportion of subjects
with a history of smoking (73%). The re-
lation of obesity measures to colorectal
adenoma might only be detected in pop-
ulations with no or low-level exposure to
smoking, as suggested by a positive ﬁnd-
ingamongnonsmokers(7).Alternatively,
if the major role of obesity in colorectal
carcinogenesis is to enlarge existing ade-
nomas, the present null ﬁnding may be
ascribable to the small number of case
subjects with large adenomas (10 mm:
n  15).
The insulin hypothesis has been pro-
posed to explain the association between
obesity or visceral adiposity and colorec-
tal cancer (12,13). Prospective studies
haveshownanincreasedriskofcolorectal
cancer among individuals with higher
Table 1—Characteristics of study subjects
Colorectal adenoma Colorectal cancer
Case
subjects
Control
subjects
Case
subjects
Control
subjects
n 86 258 22 66
Sex (% women) 3.5 3.5 4.6 4.6
Age (years) 54.0  6.4 54.0  6.4 53.8  7.9 53.8  7.7
Smoking (%)
Lifetime nonsmoker 15.1 26.0 13.6 21.2
600 cigarette-years 38.4 36.1 45.5 39.4
600 cigarette-years 46.5 38.0 40.9 39.4
Alcohol use (%)
Nondrinker 24.4 26.7 22.7 40.9
Drinking 1 go/day 37.2 41.9 36.4 27.3
Drinking 1 go/day 38.4 31.4 40.9 31.8
BMI (kg/m
2) 23.7  3.0 23.8  2.9 25.5  3.8 23.7  2.9
Waist circumference (cm) 85.2  8.5 85.9  8.7 89.5  14.6 84.4  8.0
Total fat area (cm
2) 247  101 253  95 290  120 240  93
Visceral fat area (cm
2) 122  56 124  52 140  42 115  54
Subcutaneous fat area (cm
2) 125  57 129  55 150  87 125  52
Fasting glucose (mg/dl) 106  20 108  19 118  39 109  20
Fasting insulin (U/dl) 6.7  4.3 6.9  4.1 9.2  7.5 7.3  4.4
HOMA-IR 1.79  1.26 1.88  1.27 2.71  2.49 2.02  1.36
Data are means  SD unless stated otherwise.
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peptide (20,21), a measure of average in-
sulin secretion, and fasting glucose (4) at
baseline, although the association with
fasting insulin was less clear (4). In accor-
dance with these data, we observed an
increase, albeit without statistical signiﬁ-
cance, in the odds of colorectal cancer in
subjects with higher levels of markers of
insulinresistance,particularlyfastingglu-
cose. With regard to colorectal adenoma,
although some studies have demon-
stratedanelevatedriskamongindividuals
with higher levels of fasting insulin (22)
or fasting glucose (23), our data do not
support a role of insulin resistance in the
development of colorectal adenoma. Re-
cently, Tabuchi et al. (24) reported similar
ﬁndings in health checkup participants
who underwent total colonoscopy: hyper-
glycemia was associated with an increased
risk of colorectal cancer, but not with
colorectal adenoma. Similarly, Chung et
al. (25) demonstrated that glucose con-
centrationsweremorestronglyassociated
with colorectal cancer than with ade-
noma. Further studies are required to de-
termine whether insulin resistance and
resulting conditions, including hyperin-
sulinemia and hyperglycemia, are more
strongly involved in the development of
cancer than in that of adenoma.
The present study has several meth-
odological advantages over previous
studiesthatdirectlymeasuredvisceralad-
iposity accumulation using CT. Control
subjects were randomly selected from a
population of screening participants,
among whom the cases arose, and ab-
dominal CT measurement was done be-
fore the diagnosis of colorectal neoplasia,
precluding the possibility of bias in the
selection of control subjects and assess-
ment of exposure, both of which are ma-
jor concerns in case-control studies.
Several limitations of the study also
warrant mention. First, the number of
case subjects with colorectal cancer was
small (n  22). Nevertheless, we were
able to detect a statistically signiﬁcant as-
sociation with visceral fat area. Second,
although the control subjects were se-
lected from among examinees with a neg-
ative screening result, they were not
conﬁrmed to be polyp free and thus may
haveincludedpatientswithcolorectalad-
enomas, leading to attenuation of the as-
sociation. Given the low probability that
the control series included subjects with
undetected cancer, however, we believe
that the present estimates for cancer were
notsubjecttoseriousbias.Third,physical
activity, a convincing protective factor for
colorectal cancer (1), was not controlled
for in the analysis; in any case, such con-
trol would not be methodologically valid
if physical activity exerted an anticarcino-
genic effect by decreasing visceral fat. An
additional limitation was the lack of con-
sideration of dietary factors. Finally, be-
cause the majority of study subjects were
male employees working for a large-scale
company in Japan, the results may not be
generalizable to populations with differ-
ent backgrounds.
In summary, the present study of
screening participants who underwent
abdominal CT scanning provides direct
evidence for the hypothesis that visceral
fat accumulation and insulin resistance
promote carcinogenesis of the colorec-
Table 2—Associations of measures of obesity with the prevalence of adenoma and cancer in the colorectum
Colorectal adenoma Colorectal cancer
1 (low) 2 3 (high) Ptrend 1 (low) 2 3 (high) Ptrend
n 86 22
Total fat area (cm
2)* 214 214–288 288 197 197–287 287
No. of case subjects/control
subjects 33/85 22/86 31/87 4/21 8/22 10/23
Crude OR (95% CI)† 1 0.63 (0.32–1.23) 0.87 (0.43–1.74) 0.2 1 2.04 (0.52–7.96) 2.44 (0.63–9.44) 0.2
Multivariable OR (95% CI)‡ 1 0.64 (0.32–1.27) 0.87 (0.43–1.76) 0.2 1 2.26 (0.52–9.82) 2.76 (0.64–11.87) 0.19
Visceral fat area (cm
2)* 103 103–142 142 92 92–129 129
No. of case subjects/control
subjects 29/85 27/86 30/87 3/21 6/22 13/23
Crude OR (95% CI)† 1 0.90 (0.44–1.85) 1.02 (0.46–2.24) 0.2 1 1.88 (0.42–8.35) 4.87 (1.11–21.42) 0.03
Multivariable OR (95% CI)‡ 1 0.86 (0.41–1.78) 0.99 (0.45–2.20) 0.2 1 2.17 (0.45–10.46) 5.92 (1.22–28.65) 0.02
Multivariable OR (95% CI)§ 1 0.89 (0.41–1.97) 1.08 (0.42–2.81) 0.2 1 2.09 (0.41–10.70) 8.42 (0.80–88.56) 0.08
Subcutaneous fat area (cm
2)* 106 106–139 139 101 101–145 145
No. of case subjects/control
subjects 30/85 31/86 25/87 7/21 7/22 8/23
Crude OR (95% CI)† 1 1.0 (0.55–1.83) 0.78 (0.40–1.52) 0.2 1 0.96 (0.26–3.46) 1.04 (0.30–3.66) 0.2
Multivariable OR (95% CI)‡ 1 1.01 (0.55–1.87) 0.82 (0.41–1.61) 0.2 1 1.17 (0.30–4.51) 1.08 (0.29–4.00) 0.2
Waist circumference (cm)* 82 82–89 89 80 80–88 88
No. of case subjects/control
subjects 24/83 32/87 30/88 6/21 4/22 12/23
Crude OR (95% CI)† 1 1.28 (0.69–2.38) 1.22 (0.61–2.42) 0.2 1 0.70 (0.18–2.78) 2.01 (0.58–6.95) 0.2
Multivariable OR (95% CI)‡ 1 1.37 (0.73–2.55) 1.18 (0.59–2.35) 0.2 1 0.75 (0.18–3.13) 2.03 (0.57–7.25) 0.2
BMI (kg/m
2) 22.5 22.5–24.8 24.8 22.2 22.2–24.8 24.8
No. of case subjects/control
subjects 29/84 29/85 28/89 3/20 8/23 11/23
Crude OR (95% CI)† 1 0.98 (0.53–1.83) 0.89 (0.46–1.73) 0.2 1 2.32 (0.56–9.68) 3.65 (0.81–16.44) 0.2
Multivariable OR (95% CI)‡ 1 0.99 (0.52–1.86) 0.90 (0.46–1.77) 0.2 1 3.00 (0.61–14.86) 4.38 (0.82–23.25) 0.09
*Measured by abdominal CT at the umbilical level in supine position. †Crude. ‡Adjusted for smoking and alcohol drinking. §Additionally adjusted for BMI.
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various hormones that may play a role
in the development and progression of
cancer not only through their effect on
insulin resistance but also by directly
controlling cell proliferation, the bio-
logical mechanisms linking visceral fat
disposition to cancer risk should be fur-
ther explored.
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